3 documents found, page 1 of 1
SAFETY AND EFFICACY OF DOLUTEGRAVIR BASED TRIPLE THERAPY IN HIV-2 INFECTION
Lopes, Maria João; Pacheco, Patrícia; Marques, Nuno; Mansinho, Kamal; Araújo, Vânia; Janeiro, Nuno; Lopes, Cristina; Rodrigues, Paulo; Maltez, FernandoDatabase solution for an HIV-2 cohort study Publication "Real-world experience of TAF/FTC/BIC in people with HIV-2" presented at European AIDS Clinical Society Conference, Oct 2023, Warsaw HIV-2 salvage therapy with Lenacapavir (injectable, capsid inhibitor, EMA approved 2022)
Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodoma...
Marcelino, Rute; Gramacho, Filipa; Martin, Francisco; Brogueira, Pedro; Janeiro, Nuno; Afonso, Cláudia; Badura, Robert; Valadas, Emília; Mansinho, KamalThe ectodomain of gp41 is the target of potent binding and neutralizing antibodies (NAbs) and is being explored in new strategies for antibody-based HIV vaccines. Previous studies have suggested that the W164A-3S (3S) and EC26-2A4 (EC26) peptides located in the gp41 ectodomain may be potential HIV vaccine candidates. We assessed 3S- and EC26-specific binding antibody responses and related neutralizing activity ...
Toscana virus in the Portuguese population: serosurvey and clinical cases.
Amaro, Fátima; Luz, Teresa; Parreira, Paulo; Ciufolini, Maria Grazia; Marchi, Antonella; Janeiro, Nuno; Zagalo, Alexandra; Proença, PaulaToscana virus (Phlebovirus genus, Bunyaviridae family) is a neurotropic virus which circulates in the Mediterranean Basin. Although Portugal has been the second country where its presence was reported, the existence of this virus in our country has been referred only sporadically, and there is a lack of knowledge regarding the prevalence of antibodies in the population. Thus, the objective of this study was to ...